SGBI Stock Overview
Through its subsidiaries, engages in the manufacturing and sales of wound treatment and cosmetic products. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
Sangui Biotech International, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €0.0015 |
| 52 Week High | €0.02 |
| 52 Week Low | €0.0012 |
| Beta | -0.33 |
| 11 Month Change | 0% |
| 3 Month Change | 25.00% |
| 1 Year Change | n/a |
| 33 Year Change | -97.73% |
| 5 Year Change | -94.13% |
| Change since IPO | -99.95% |
Recent News & Updates
Recent updates
Shareholder Returns
| SGBI | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 0% | 2.5% | 2.2% |
| 1Y | n/a | 16.1% | 31.6% |
Return vs Industry: Insufficient data to determine how SGBI performed against the US Biotechs industry.
Return vs Market: Insufficient data to determine how SGBI performed against the US Market.
Price Volatility
| SGBI volatility | |
|---|---|
| SGBI Average Weekly Movement | n/a |
| Biotechs Industry Average Movement | 9.8% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 15.7% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: SGBI has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine SGBI's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1995 | n/a | Thomas Striepe | www.sanguibiotech.com |
Sangui Biotech International, Inc., through its subsidiaries, engages in the manufacturing and sales of wound treatment and cosmetic products. The company offers artificial oxygen carriers comprising oxygen carrying blood additives and oxygen carrying blood volume substitutes; nano formulations for the regeneration of skin; chitoskin wound pads; Hemospray, a hemoglobin based wound spray; and wound dressing spray under the Granulox brand. Sangui Biotech International, Inc. was incorporated in 1995 and is headquartered in Hamburg, Germany.
Sangui Biotech International, Inc. Fundamentals Summary
| SGBI fundamental statistics | |
|---|---|
| Market cap | US$446.65k |
| Earnings (TTM) | -US$100.32k |
| Revenue (TTM) | US$96.26k |
4.6x
P/S Ratio-4.5x
P/E RatioIs SGBI overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| SGBI income statement (TTM) | |
|---|---|
| Revenue | US$96.26k |
| Cost of Revenue | US$0 |
| Gross Profit | US$96.26k |
| Other Expenses | US$196.58k |
| Earnings | -US$100.32k |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.00048 |
| Gross Margin | 100.00% |
| Net Profit Margin | -104.22% |
| Debt/Equity Ratio | -72.8% |
How did SGBI perform over the long term?
See historical performance and comparison